Adipotide
Also called FTPP, Prohibitin-targeting peptide
No single human route established in this referenceAnimal / laboratory reference
Research reference
Animal / laboratory study
Adipotide obese-monkey experiment
Animal dosing only; no human amount supplied
Four-week animal exposure with recovery observations
Barnhart et al., Science Translational Medicine (2011) ↗When results may show
Adipotide
Evidence gap- When change was measured
- Weight and metabolic changes were measured in monkeys; kidney injury signals were also investigated.
- When to assess
- Four-week animal exposure with recovery observations
- Conditions and limitations
- Obese nonhuman primates. Kidney toxicity and species differences prevent a defensible human starter or personal quit rule. Animal weight loss is not a human safety result.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 10hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Barnhart et al., Science Translational Medicine (2011)Kidney toxicity and species differences prevent a defensible human starter or personal quit rule. Animal weight loss is not a human safety result.